XTX Topco Ltd lifted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 634.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 256,714 shares of the company's stock after acquiring an additional 221,742 shares during the period. XTX Topco Ltd's holdings in Roivant Sciences were worth $2,590,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC boosted its stake in Roivant Sciences by 0.3% during the fourth quarter. FMR LLC now owns 49,301,583 shares of the company's stock worth $583,238,000 after buying an additional 156,527 shares in the last quarter. Vanguard Group Inc. boosted its stake in Roivant Sciences by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after buying an additional 2,404,232 shares in the last quarter. Patient Square Capital LP boosted its stake in Roivant Sciences by 2.1% during the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company's stock worth $147,638,000 after buying an additional 251,535 shares in the last quarter. Two Seas Capital LP boosted its stake in shares of Roivant Sciences by 4.6% in the 4th quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock valued at $120,285,000 after purchasing an additional 442,914 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Roivant Sciences by 49.7% in the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock valued at $112,563,000 after purchasing an additional 3,159,603 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the stock. The Goldman Sachs Group upgraded shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 target price on the stock in a research note on Thursday, July 10th. HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, June 18th.
Get Our Latest Stock Report on ROIV
Insider Transactions at Roivant Sciences
In related news, COO Eric Venker sold 566,278 shares of Roivant Sciences stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $11.22, for a total value of $6,353,639.16. Following the completion of the transaction, the chief operating officer directly owned 1,462,223 shares of the company's stock, valued at $16,406,142.06. The trade was a 27.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Vivek Ramaswamy sold 577,007 shares of the business's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $11.46, for a total value of $6,612,500.22. Following the sale, the insider directly owned 37,284,108 shares of the company's stock, valued at $427,275,877.68. This represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,464,462 shares of company stock valued at $39,228,856 over the last ninety days. 7.90% of the stock is currently owned by company insiders.
Roivant Sciences Trading Down 0.4%
Shares of Roivant Sciences stock traded down $0.05 during trading on Friday, reaching $11.31. The company's stock had a trading volume of 2,910,651 shares, compared to its average volume of 4,908,361. The stock has a 50-day moving average price of $11.27 and a two-hundred day moving average price of $10.86. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06. The stock has a market capitalization of $7.69 billion, a P/E ratio of -45.24 and a beta of 1.15.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Thursday, May 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). Roivant Sciences had a negative net margin of 225.71% and a negative return on equity of 14.76%. The business had revenue of $7.57 million during the quarter, compared to the consensus estimate of $62.17 million. During the same period in the prior year, the firm earned ($0.23) earnings per share. As a group, sell-side analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access